Researchers at The University of Texas MD Anderson Cancer Center have identified a unique 'molecular fingerprint' in the blood of patients with inflammatory breast cancer (IBC), comprising five blood-based biomarkers. Published on January 16, 2024, in *Nature Communications*, this discovery aims to address the challenges of early detection and treatment for IBC, a rare and aggressive form of breast cancer that is often misdiagnosed and progresses rapidly.
The study utilized advanced proteomic technologies to analyze blood samples from IBC patients and control subjects, leading to the identification of four proteins—SPP1, ANXA2, COL6A3, THBS2—and one microRNA, miR-18a-5p. Further analysis revealed that a specific signature combining three of these biomarkers—SPP1, miR-18a-5p, and COL6A3—demonstrated the best performance in distinguishing IBC patients from individuals without the disease. Dr. Debu Tripathy, the lead author, stated, 'We're hopeful this set of biomarkers will provide early diagnosis and help monitor treatment response for IBC patients.'
These identified biomarkers hold promise as a non-invasive tool for the earlier detection of IBC and could also be utilized for monitoring treatment responses, thereby improving patient prognosis. The researchers plan to conduct further validation of these findings in larger and more diverse patient cohorts to confirm their clinical utility and integrate them into diagnostic and prognostic strategies. This research represents a crucial step towards developing more effective management strategies for inflammatory breast cancer.
